Stimuli-responsive polymer-doxorubicin conjugate: Antitumor mechanism and potential as nano-prodrug.

Polymer-drug conjugates has significantly improved the anti-tumor efficacy of chemotherapeutic drugs and alleviated their side effects. N-(1,3-dihydroxypropan-2-yl) methacrylamide (DHPMA) copolymer was synthesized via RAFT polymerization and polymer-doxorubicin (DOX) (diblock pDHPMA-DOX) were formed by conjugation, resulting in a self-aggregation-induced nanoprodrug with a favorable size of 21 nm and great stability. The nanoprodrug with a molecular weight (MW) of 95 kDa released drugs in response to tumor microenvironmental pH variations and they were enzymatically hydrolyzed into low MW segments (45 kDa). The nanoprodrug was transported through the endolysosomal pathway, released the drug into the cytoplasm and some was localized in the mitochondria, resulting in disruption of the cellular actin cytoskeleton. Cellular apoptosis was also associated with reduction in the mitochondrial potential caused by the nanoprodrug. Notably, the nanoprodrug had a significantly prolonged blood circulation time with an elimination half time of 9.8 h, displayed high accumulation within tumors, and improved the in vivo therapeutic efficacy against 4T1 xenograft tumors compared to free DOX. The tumor xenograft immunohistochemistry study clearly indicated tumor inhibition was through the inhibition of cell proliferation and antiangiogenic effects. Our studies demonstrated that the diblock pDHPMA-DOX nanoprodrug with a controlled molecular structure is promising to alleviate adverse effects of free DOX and have a great potential as an efficient anticancer agent. STATEMENT OF SIGNIFICANCE: In this work, we prepared a biodegradable diblock DHPMA polymer-doxorubicin conjugate via one-pot of RAFT polymerization and conjugate chemistry. The conjugate-based nanoprodrug was internalized by endocytosis to intracellularly release DOX and further induce disruption of mitochondrial functions, actin cytoskeleton alterations and cellular apoptosis. The nanoprodrug with a high molecular weight (MW) (95 kDa) showed a long blood circulation time and achieved high accumulation into tumors. The nanoprodrug was degraded into low MW (∼45 kDa) products below the renal threshold, which ensured its biosafety. Additionally, the multi-stimuli-responsive nanoprodrug demonstrated an enhanced antitumor efficacy against 4T1 breast tumors and alleviated side effects, showing a great potential as an efficient and safe anticancer agent.
AuthorsKai Chen, Hao Cai, Hu Zhang, Hongyan Zhu, Zhongwei Gu, Qiyong Gong, Kui Luo
JournalActa biomaterialia (Acta Biomater) Vol. 84 Pg. 339-355 (01 15 2019) ISSN: 1878-7568 [Electronic] England
PMID30503561 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Delayed-Action Preparations
  • Prodrugs
  • Stimuli Responsive Polymers
  • Doxorubicin
  • Animals
  • Cell Line, Tumor
  • Delayed-Action Preparations (chemistry, pharmacokinetics, pharmacology)
  • Doxorubicin (chemistry, pharmacokinetics, pharmacology)
  • Female
  • Mammary Neoplasms, Experimental (drug therapy, metabolism, pathology)
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles (chemistry, therapeutic use)
  • Prodrugs (chemistry, pharmacokinetics, pharmacology)
  • Stimuli Responsive Polymers (chemistry, pharmacokinetics, pharmacology)
  • Tumor Microenvironment (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: